Form 4 for NUVB Nuvation Bio Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2021-03-02 · accession 0001209191-23-014890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2021-03-02 | NUVB | Hung David | Pres, CEO, Dir, 10% | J - Other | $0.00 | -368.4K | 58.28M | -0.6% | $0 |
| D | 2023-03-02 | 2023-02-28 | NUVB | Hung David | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +2.50M | 2.50M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-03-02 | J | D | 368,408 | $0.00 | 58,281,054 | D | — | — | (F1) On March 2, 2021, the Reporting Person surrendered 368,408 shares of the Issuer's Class A Common Stock in connection with the satisfaction of the Issuer's obligations to GiraFpharma LLC. (F2) Includes 2,661 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-28 | A | A | 2,500,000 | $0.00 | 2,500,000 | D | $1.94 · — to 2033-02-27 | 2,500,000 Class A Common Stock | (F3) Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |